Navigation Links
Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010
Date:3/17/2010

QUÉBEC CITY, March 17 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, will announce its fourth quarter and full year 2009 financial and operating results before market open on Wednesday, March 24, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 888-231-8191 (North America), or 647-427-7450 or 514-807-9895 (Canada). A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Æterna Zentaris Inc.

Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are availabl
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
2. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
3. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
4. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Genome Research Institute (NHGRI) of the National Institutes of ... to date to chart the genetic changes involved in ... The findings should help pave the way for more ... cause of cancer deaths. , In a paper published ...
... team of scientists has performed the ultimate miniaturisation of ... atom. This breakthrough is a key step in bringing ... on the fundamental theory of quantum mechanics which could ... quantum world, objects such as atoms are allowed to ...
... PALO ALTO, Calif., Oct. 22 Telik, Inc.,(Nasdaq: ... call and,webcast will be held on Wednesday, November 5, ... following the release earlier that day of the,company,s financial ... The conference call will be accessible via Telik,s ...
Cached Biology Technology:Large-scale genetic study sheds new light on lung cancer 2Large-scale genetic study sheds new light on lung cancer 3Large-scale genetic study sheds new light on lung cancer 4Large-scale genetic study sheds new light on lung cancer 5Memoirs of a qubit: Hybrid memory solves key problem for quantum computing 2
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... Biofuels based on ethanol, vegetable oil and other renewable ... a way to reduce fossil fuel dependence and limit ... a biologist at the University of Washington, Bothell, shows ... might have exactly the opposite impacts than intended. The ...
... Clouds have typically posed a problem to scientists using ... where humans live and breathe, because they block the ... Earth,s surface. It turns out, however, that these "obstructions" ... characteristics actually serve a valuable role in Earth,s climate. ...
... RELEASE, 26 May 2008] Scientists at the Swedish medical ... that is much cheaper than those currently in use ... make it possible to map disease genes in large ... for new treatments for a wide variety of diseases. ...
Cached Biology News:Some biofuels might do more harm than good to the environment, study finds 2Some biofuels might do more harm than good to the environment, study finds 3Satellites illuminate pollution's influence on clouds 2Satellites illuminate pollution's influence on clouds 3New cheaper method for mapping disease genes 2
... The Bioactive peptides are molecules of peptidic ... behaviour or activity which can be developed ... chemical and agro-food applications. In this way ... with superior properties for therapeutic applications. Primm ...
... InnoScan700 is a fluorescence scanner with ... biochip (Staggered/Orange Packing, Protein, CGH, ) spotted ... the range of InnoScan700 scanners include three ... InnoScan700A is a simultaneous dual fluorescence scanner ...
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
... DNAscope is an integrated confocal laser scanner ... integrated into your specific application. GeneFocus can ... tailor the system to your specifications. ... design has been modularized and built onto ...
Biology Products: